PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Both companies show declining cash positions (-3.88% vs TRAW's -8.42%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of TRAW's -8.42%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Above 1.5x TRAW's -0.98%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-4.12%
Below half of TRAW's -8.91%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
Below half TRAW's -9.68%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
1.1-1.25x TRAW's -90.00%. Bill Ackman questions if the firm invests in intangible or other non-core areas more aggressively.
-3.14%
Below half of TRAW's -29.27%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Below half of TRAW's -8.93%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.45%
1.25-1.5x TRAW's 25.21%. Martin Whitman sees potential reliance on supplier financing. Verify liquidity.
25.40%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-25.40%
Less than half of TRAW's -53.65%. David Dodd sees fewer expansions in other current obligations.
32.92%
Above 1.5x TRAW's 13.56%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of TRAW's -1.82%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.45%
50-75% of TRAW's 8.54%. Bruce Berkowitz notes a lower yoy liability increase.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
≥ 1.5x TRAW's -1.19%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
0.5-0.75x TRAW's -13.29%. Martin Whitman is wary of lagging equity growth vs. competitor.
-4.09%
Below half TRAW's -8.93%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
3.93%
Less than half of TRAW's 8.42%. David Dodd sees better deleveraging or stronger cash buildup than competitor.